Impact of extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-E) rectal carriage in cancer patients admitted to the intensive care unit

Infect Dis Now. 2022 Mar;52(2):104-106. doi: 10.1016/j.idnow.2021.12.004. Epub 2021 Dec 15.

Abstract

Little data is available on extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-E) rectal colonization in cancer patients admitted to the intensive care unit (ICU). We aimed to describe the epidemiology of ESBL-E in cancer patients hospitalized in the ICU compared with non-cancer patients. ESBL-E colonization was detected in 6.6% of 1,013 cancer patients and 6.4% of 1625 non-cancer patients. At admission, among the 172 colonized patients: 48/67 cancer patients and 78/105 non-cancer patients developed an infection, documented with an ESBL-E for 21% and 24% of them, respectively. The in-hospital mortality rate among colonized patients was 33% in cancer patients and 12% in non-cancer patients. In cancer patients, ESBL-E infections are rare but systematic rectal screening identifies high-risk population and guides empirical antibiotic therapy. It also contributes to being aware of the ICU microbiological ecology.

Keywords: Cancer patients; Colonization; ESBL-E; Infection.

MeSH terms

  • Carrier State / epidemiology
  • Carrier State / microbiology
  • Cross Infection* / drug therapy
  • Cross Infection* / epidemiology
  • Enterobacteriaceae Infections* / drug therapy
  • Enterobacteriaceae Infections* / epidemiology
  • Humans
  • Intensive Care Units
  • Neoplasms*
  • beta-Lactamases

Substances

  • beta-Lactamases